trial · primary record
Linvoseltamab
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 387 |
| Primary completion | 2033-06-16 |
| Primary endpoint | Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period |
| Registry ID | NCT03761108 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:30.952Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03761108
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.